PRAH
-1.67%(-2.80)
Open
167.73
Prev Close
168.01
Day High
165.21
Day Low
165.21
Volume
57
Avg Volume
1.6M
52W High
165.21
52W Low
93.00
Signal
Bearish Setup2
Price
1
Move-1.67%Negative session
Volume
1
Volume0.0× avgLight volume
Technical
1
RSIRSI 38Momentum negative
PRICE
Prev Close
168.01
Open
167.73
Day Range
52W Range93.00 – 165.21
93.00
165.21
100% of range
VOLUME & SIZE
Avg Volume
1.6M
FUNDAMENTALS
P/E Ratio
50.5x
Premium valuation
EPS (TTM)
Div Yield
No dividend
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +7% YoY
Valuation
EXPENSIVE
P/E 51x vs ~20x sector
Health
MODERATE
CR 1.2 · FCF $5.51/sh
Lean Bullish
Key MetricsTTM
Market Cap$10.70B
Revenue TTM$3.33B
Net Income TTM$213.32M
Free Cash Flow$494.72M
Gross Margin27.3%
Net Margin6.2%
Operating Margin8.9%
Return on Equity15.3%
Return on Assets4.7%
Debt / Equity0.86
Current Ratio1.15
EPS TTM$3.02

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong2 watch1 concern
48/100
Liquidity
1.15Watch
Leverage
0.86Strong
Coverage
6.6xStrong
ROE
15.3%Strong
ROIC
7.1%Concern
Cash
$506MWatch
Analyst Coverage

No analyst coverage available for this stock.

Upcoming Events
EEarnings ReportMay 4, 2026
Tomorrow
DEx-Dividend DateJul 31, 2026
In 89 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

PullbackGolden Cross · 50D leads 200D by 1156.6%

-2.4% vs SMA 50 · +1126.8% vs SMA 200

Momentum

RSI37.8
Momentum fading
MACD-0.74
Below zero — bearish pulse · compressing
Market Position
Price Levels
EMA 50
$165.8+0.4%
52W High
$165.2+0.0%
Current
$165.2
52W Low
$93.00-43.7%
EMA 200
$13.47-91.8%
52-Week RangeNear 52-week high
$93.00100th %ile$165.2
Earnings & Analysts
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
Bonello Michael J.EVP & CFO
$1.1M
Jun 16
SELL
Bonello Michael J.EVP & CFO
$100K
Jun 16
SELL
Bonello Michael J.EVP & CFO
$33K
Jun 16
SELL
Shannon ColinDir
$1.2M
Jun 16
SELL
Shannon ColinDir
$94K
Jun 16
SELL
Shannon ColinDir
$72K
Jun 16
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
Marshall Wace North America L.P.
0
2
World Asset Management Inc
0
3
Covenant Multifamily Offices, LLC
0
4
Omni Partners US LLC
0
5
Berman Capital Advisors, LLC
0
6
QS Investors, LLC
1K
7
PICTET ASSET MANAGEMENT LTD
0
8
AMUNDI ASSET MANAGEMENT US, INC.
5K
News & Activity

PRAH News

20 articles · 4h ago

About

PRA is one of the world's leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 18,100 employees worldwide. Since 2000, PRA has participated in approximately 4,200 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 100 drugs.

Industry
Research and Development in Biotechnology
Country
United States